184 related articles for article (PubMed ID: 6221540)
41. Comparison of the vascular responses to various prostanoic compounds in the puppy and adult dog.
Fitzpatrick T; Harris R; Ramwell P; Kot P
Adv Prostaglandin Thromboxane Res; 1980; 7():727-9. PubMed ID: 6989200
[No Abstract] [Full Text] [Related]
42. Vasodilation and inhibition of platelet aggregation by prostacyclins with modified omega-side chain.
Schölkens BA; Bartmann W; Beck G; Lerch U; Konz E; Weithmann U
Prostaglandins Med; 1979 Jul; 3(1):7-22. PubMed ID: 399529
[TBL] [Abstract][Full Text] [Related]
43. Antithrombotic and vasodilating effects of OP-41483, a prostacyclin derivative.
Kinjo O; Kusaba A; Uesato T; Shiroma H; Koja K; Kina M; Kuniyoshi Y; Iha K; Shiohira T; Kawabata T
Int Angiol; 1987; 6(3):279-85. PubMed ID: 3329206
[TBL] [Abstract][Full Text] [Related]
44. Relaxin inhibits prostacyclin release by the rat pregnant myometrium.
Williams KI; El Tahir KE
Prostaglandins; 1982 Aug; 24(2):129-36. PubMed ID: 6815714
[TBL] [Abstract][Full Text] [Related]
45. Comparative study on the prostacyclin producing activities in bovine heart valves.
Honda A; Morita I; Mori Y; Murota S
Thromb Res; 1981 May; 22(3):381-6. PubMed ID: 6795748
[No Abstract] [Full Text] [Related]
46. 11- and 15-deoxy-carboprostacyclins: hypothetic prostacyclin antagonists.
Mongelli N; Magni O; Gandolfi C; Grossoni M; Ceserani R
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():281-5. PubMed ID: 6221538
[No Abstract] [Full Text] [Related]
47. Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion.
Charo IF; Feinman RD; Detwiler TC; Smith JB; Ingerman CM; Silver MJ
Nature; 1977 Sep; 269(5623):66-9. PubMed ID: 895887
[No Abstract] [Full Text] [Related]
48. Platelets from diabetic subjects show diminished sensitivity to prostacyclin.
Betteridge DJ; El Tahir KE; Reckless JP; Williams KI
Eur J Clin Invest; 1982 Oct; 12(5):395-8. PubMed ID: 6816610
[TBL] [Abstract][Full Text] [Related]
49. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
[TBL] [Abstract][Full Text] [Related]
50. 20-Methyl-prostacyclin analogs--a two stage screening procedure for biological properties.
Gandolfi CA; Gryglewski RJ
Pharmacol Res Commun; 1978 Nov; 10(10):885-96. PubMed ID: 366628
[No Abstract] [Full Text] [Related]
51. Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog.
Johnson GJ; Rao GH; Leis LA; White JG
Blood; 1980 May; 55(5):722-9. PubMed ID: 6244866
[No Abstract] [Full Text] [Related]
52. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.
Szczeklik A; Gryglewski RJ; Nizankowski R; Musiał J; Pietoń R; Mruk J
Pharmacol Res Commun; 1978 Jun; 10(6):545-56. PubMed ID: 358212
[No Abstract] [Full Text] [Related]
53. Ingestion of dipyridamole reduces inhibitory effect of prostacyclin on human platelets.
Di Minno G; Silver MJ; De Gaetano G
Lancet; 1979 Sep; 2(8144):701-2. PubMed ID: 90798
[No Abstract] [Full Text] [Related]
54. Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog.
Skuballa W; Vorbrüggen H
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():299-305. PubMed ID: 6189381
[No Abstract] [Full Text] [Related]
55. Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers.
Virgolini I; Fitscha P; Sinzinger H; Barth H
Eur J Clin Pharmacol; 1990; 38(4):347-50. PubMed ID: 2111774
[TBL] [Abstract][Full Text] [Related]
56. Is prostacyclin a physiologically important circulating anti-platelet agent?
Steer ML; MacIntyre DE; Levine L; Salzman EW
Nature; 1980 Jan; 283(5743):194-5. PubMed ID: 6243178
[No Abstract] [Full Text] [Related]
57. Demonstration of PGI2 production by isolated perfused rat lungs with platelet aggregation test.
Hartiala J; Toivonen H; Uotila P
Prostaglandins; 1980 Jul; 20(1):127-34. PubMed ID: 6996035
[TBL] [Abstract][Full Text] [Related]
58. A prospective method for thrombotic diseases using prostaglandin I2.
Isobe J; Mizuno A
Tokushima J Exp Med; 1982 Jun; 29(1-2):95-101. PubMed ID: 6755803
[No Abstract] [Full Text] [Related]
59. Elevation of adenosine 3',5'-monophosphate levels in 3T3 fibroblasts by arachidonic acid: evidence for mediation by prostaglandin I2.
Claesson HE; Lindgren JA; Hammarström S
FEBS Lett; 1977 Sep; 81(2):415-8. PubMed ID: 200482
[No Abstract] [Full Text] [Related]
60. 9,11-Epoxy-9-homo-14-oxaprosta-5-enoic acid derivatives. Novel inhibitors of fatty acid cyclooxygenase.
Hall SE; Han WC; Haslanger MF; Harris DN; Ogletree ML
J Med Chem; 1986 Nov; 29(11):2335-47. PubMed ID: 3097316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
